Structurally modified anthracyclines retain activity in a cell line with simultaneous typical and atypical multidrug resistance.
Standard
Structurally modified anthracyclines retain activity in a cell line with simultaneous typical and atypical multidrug resistance. / Bielack, S S; Kallenbach, K; Looft, G; Erttmann, Rudolf; Winkler, K.
in: ANTICANCER RES, Jahrgang 15, Nr. 4, 4, 1995, S. 1279-1284.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Structurally modified anthracyclines retain activity in a cell line with simultaneous typical and atypical multidrug resistance.
AU - Bielack, S S
AU - Kallenbach, K
AU - Looft, G
AU - Erttmann, Rudolf
AU - Winkler, K
PY - 1995
Y1 - 1995
N2 - Resistance to the classical anthracyclines may be due to one or several mechanisms, most notably p-glycoprotein (pGP) associated multidrug resistance (mdr1, "typical mdr") and altered activity of topoisomerase II (topo II) ("atypical mdr"). Modulators of mdr1 will be of limited value in case of combined forms of resistance. A Friend murine erythroleukemia cell line (F4-6R) carrying both mdrl and topo II mediated anthracycline resistance was used to determine the efficacy of structurally altered anthracyclines against such extended multidrug resistance. Proliferation assays showed that 3'N-morpholinyl substituted anthracyclines were able to retain much of their activity even in this setting. MX2 (KRN8602; 3'-deamino-3'-[4-morpholinyl]-13-deoxo-10-hydroxycarminomycin+ ++), which is 9-alkylated in addition to carrying a 3'N-morpholinyl group, was the most promising agent tested.
AB - Resistance to the classical anthracyclines may be due to one or several mechanisms, most notably p-glycoprotein (pGP) associated multidrug resistance (mdr1, "typical mdr") and altered activity of topoisomerase II (topo II) ("atypical mdr"). Modulators of mdr1 will be of limited value in case of combined forms of resistance. A Friend murine erythroleukemia cell line (F4-6R) carrying both mdrl and topo II mediated anthracycline resistance was used to determine the efficacy of structurally altered anthracyclines against such extended multidrug resistance. Proliferation assays showed that 3'N-morpholinyl substituted anthracyclines were able to retain much of their activity even in this setting. MX2 (KRN8602; 3'-deamino-3'-[4-morpholinyl]-13-deoxo-10-hydroxycarminomycin+ ++), which is 9-alkylated in addition to carrying a 3'N-morpholinyl group, was the most promising agent tested.
M3 - SCORING: Zeitschriftenaufsatz
VL - 15
SP - 1279
EP - 1284
JO - ANTICANCER RES
JF - ANTICANCER RES
SN - 0250-7005
IS - 4
M1 - 4
ER -
